PharmTech LCGC Sciex Webinar 11.10
|Articles|April 15, 2009

Waters UHPLC Systems Purchased for Metabolomics Research

Waters Corporation (Milford, Massachusetts) announced that the National Cancer Institute?s Center for Cancer Research (Bethesda, Maryland) has purchased the company?s ACQUITY UPLC?Synapt High Definition mass spectrometry (MS) and ACQUITY UPLC?Xevo TQ MS systems for metabolomics research programs.

Waters Corporation (Milford, Massachusetts) announced that the National Cancer Institute’s Center for Cancer Research (Bethesda, Maryland) has purchased the company’s ACQUITY UPLC–Synapt High Definition mass spectrometry (MS) and ACQUITY UPLC–Xevo TQ MS systems for metabolomics research programs. The research is intended to discover small molecule metabolites or biomarkers associated with cancer susceptibility and diagnosis, treatment efficacy, and adverse effects of medicines and other chemicals. The research requires sensitive analytical instrumentation capable of analyzing thousands of samples per month.


Related to this article

Best of the Week: From Cancer Diagnostics to Smarter LC Method Development
This week, Chromatography Online’s coverage spanned lipidomics-based early cancer detection, career paths in separation science, machine learning and uncertainty-driven approaches to LC method development, new EU wastewater rules for pharmaceutical micropollutants, automated Separation Quality Factor (SQF) evaluation in chromatography data systems, and solutions to GLP-1 peptide analysis challenges.